2--propionic acid | 118618-37-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2--propionic acid
• 英文别名: 2-[4-(Aminomethyl)phenoxy]propanoic acid
• CAS: 118618-37-4
• 化学式: C₁₀H₁₃NO₃
• 分子量: 195.218
• InChiKey: HLXIXIIMNPKITF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  乙醇 、 2--propionic acid 在 硫酸 作用下， 反应 22.0h， 以72%的产率得到ethyl 2--propionate
  参考文献：
  名称：

  Biagi; Livi; Scartoni, Farmaco, Edizione Scientifica, 1988, vol. 43, # 7-8, p. 597 - 611

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(p-amino-phenoxy)-propionic acid 在 氢气 、 镍 、 sodium carbonate 、 copper(II) sulfate 、 sodium nitrite 作用下， 以 ammonium hydroxide 为溶剂， 反应 6.25h， 生成 2--propionic acid
  参考文献：
  名称：

  Biagi; Livi; Scartoni, Farmaco, Edizione Scientifica, 1988, vol. 43, # 7-8, p. 597 - 611

  摘要：

  DOI：

文献信息

• Discovery of β-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors
  作者：Woul Seong Park、Seung Kyu Kang、Mi Ae Jun、Mi Sik Shin、Ki Young Kim、Sang Dal Rhee、Myung Ae Bae、Min Sun Kim、Kwang Rok Kim、Nam Sook Kang、Sung-eun Yoo、Jie Oh Lee、Dong Hyun Song、Peter Silinski、Stephen Edward Schneider、Jin Hee Ahn、Sung Soo Kim

  DOI：10.1016/j.bmcl.2011.01.041

  日期：2011.3

  containing thiazolidine derivatives was synthesized and evaluated for their ability to inhibit DPP-IV. Several thiazolidine derivatives with an acid moiety were found to be potent DPP-IV inhibitors. Among them, compound 2da is the most active in this series with an IC50 value of 1 nM, and it showed excellent selectivity over DPP-IV related enzymes including DPP-2, DPP-8, and DPP-9. Compound 2da is chemically

  合成了一系列含有β-氨基酰基的噻唑烷衍生物，并评估了它们抑制DPP-IV的能力。发现具有酸部分的几种噻唑烷衍生物是有效的DPP-IV抑制剂。其中，化合物2da是该系列中活性最高的化合物，IC 50值为1 nM，与DPP-IV相关的酶（包括DPP-2，DPP-8和DPP-9）相比，具有出色的选择性。化合物2da具有化学和代谢稳定性，未显示CYP抑制，hERG结合或细胞毒性。化合物2db（2da的酯类前药）在大鼠和狗模型中口服后显示出良好的体内DPP-IV抑制作用。
• Aryl dicarboxamides
  申请人：Thomas J. Russel

  公开号：US20060189583A1

  公开（公告）日：2006-08-24

  The present invention is related to aryl dicarboxamides of formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholes-terolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of aryl dicarboxamides of formula (I) to modulate, notably to inhibit the activity of PTPs. A is an aminocarbonyl moiety; Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group; n is either 0 or 1; R 1 and R 2 are independently from each other is selected from the group consisting of hydrogen or C 1 -C 6 -alkyl; R 4 and R 5 are each independently from each other selected from the group consisting of H, hydroxy, C 1 -C 6 alkyl, carboxy, C 1 -C 6 alkoxy, C 1 -C 3 alkyl carboxy, C 2 -C 3 alkenyl carboxy, C 2 -C 3 alkynyl carboxy, amino or R 4 and R 5 may form an unsaturated or saturated heterocyclic ring, whereby at least one of R 4 or R 5 is not a hydrogen or C 1 -C 6 alkyl.

  本发明涉及式（I）的芳基二羧酰胺及其用于治疗和/或预防由胰岛素抵抗或高血糖介导的肥胖症和/或代谢紊乱，包括1型和/或2型糖尿病、不良葡萄糖耐受、胰岛素抵抗、高脂血症、高三酰甘油血症、高胆固醇血症、多囊卵巢综合症（PCOS）。特别地，本发明涉及使用式（I）的芳基二羧酰胺来调节，特别是抑制PTP的活性。其中，A是氨基甲酰基；Cy是芳基、杂环芳基、芳基-杂环芳基、杂环芳基-芳基、芳基-芳基、环烷基或杂环基团；n为0或1；R1和R2各自独立地选择自氢或C1-C6烷基的群；R4和R5各自独立地选择自H、羟基、C1-C6烷基、羧基、C1-C6烷氧基、C1-C3烷基羧基、C2-C3烯基羧基、C2-C3炔基羧基、氨基或R4和R5可以形成不饱和或饱和的杂环环，其中R4或R5中至少有一个不是氢或C1-C6烷基。
• Alkynyl aryl carboxamides
  申请人：Swinnen Dominique

  公开号：US20070105913A1

  公开（公告）日：2007-05-10

  The present invention is related to alkynyl aryl carboxamides of Formula (I′) and use thereof for the treatment and/or prevention of an inflammatory disorder, obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia-hypercholesterolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of alkynyl aryl carboxamides of Formula (I′) to modulate, notably to inhibit the activity of PTPs. (I′) A is a C 2 -C 15 alkynyl, C 2 -C 6 -alkynyl aryl, C 2 -C 6 -alkynyl heteroaryl. Cy is an aryl, heteroaryl, cycloalkyl or heterocycle group; n is either 0 or 1. Cy′ is an aryl., which may optionally be fused by a 3-8 membered cycloalkyl. R 1 and R 2 are independently from each other is selected from the group consisting of hydrogen or (C 1 -C 6 )alkyl. R 4 and R 5 are each independently from each other selected from the group consisting of H, hydroxy. C 1 -C 6 alkyl, carboxy, C 1 -C 6 alkoxy, C 1 -C 3 alkyl carboxy, C 2 -C 3 alkenyl carboxy, C 2 -C 3 alkynyl carboxy, amino or R 4 and R 5 may form an unsaturated or saturated heterocyclic ring, whereby at least one of R 4 or R 5 is not a hydrogen or C 1 -C 6 alkyl.

  本发明涉及公式（I'）的炔基芳基羧酰胺及其用于治疗和/或预防由胰岛素抵抗或高血糖介导的炎症性疾病、肥胖和/或代谢紊乱，包括1型和/或2型糖尿病、不足的葡萄糖耐受性、胰岛素抵抗、高脂血症、高三酸甘油酯血症-高胆固醇血症、多囊卵巢综合征（PCOS）。特别地，本发明涉及使用公式（I'）的炔基芳基羧酰胺来调节，特别是抑制PTP的活性。 （I'）中，A是C2-C15炔基、C2-C6炔基芳基、C2-C6炔基杂芳基。Cy是芳基、杂芳基、环烷基或杂环基；n为0或1。Cy'是芳基，可以选择与3-8个成员的环烷基融合。R1和R2分别独立地选自羟基或（C1-C6）烷基的群。R4和R5各自独立地选自H、羟基、C1-C6烷基、羧基、C1-C6烷氧基、C1-C3烷基羧基、C2-C3烯基羧基、C2-C3炔基羧基、氨基或R4和R5可以形成不饱和或饱和的杂环，其中R4或R5中至少有一个不是氢或C1-C6烷基。
• 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors
  申请人：Swinnen Dominique

  公开号：US20090029903A1

  公开（公告）日：2009-01-29

  The present invention is related to carboxylic acids of Formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of carboxylic acids of Formula (I) to modulate, notably to inhibit the activity of PTPs.

  本发明涉及式（I）的羧酸及其用于治疗和/或预防由胰岛素抵抗或高血糖介导的肥胖症和/或代谢紊乱，包括糖尿病I型和/或II型、不良葡萄糖耐受性、胰岛素抵抗、高脂血症、高甘油三酯血症、高胆固醇血症、多囊卵巢综合征（PCOS）。特别地，本发明涉及使用式（I）的羧酸调节，尤其是抑制PTP活性。
• BIAGI, G.;LIVI, O.;SCARTONI, V.;VERUGI, E., FARMACO: ED. SCI., 43,(1988) N 7-8, C. 597-611
  作者：BIAGI, G.、LIVI, O.、SCARTONI, V.、VERUGI, E.

  DOI：——

  日期：——